Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BBIO NASDAQ:GMAB NASDAQ:INDV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$218.06+1.1%$232.15$160.86▼$250.74$13.60B0.39546,697 shs405,008 shsBBIOBridgeBio Pharma$66.80-1.1%$70.22$38.57▼$84.94$13.08B0.972.71 million shs1.55 million shsGMABGenmab A/S$25.08-0.6%$26.76$20.23▼$35.43$15.64B0.851.86 million shs1.11 million shsINDVIndivior$38.48+0.9%$35.44$13.45▼$41.00$4.69B0.881.68 million shs627,489 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S0.00%+3.62%-11.17%-3.50%+26.99%BBIOBridgeBio Pharma0.00%-1.20%-4.11%-3.76%+71.06%GMABGenmab A/S0.00%-0.28%-6.77%-4.06%+10.83%INDVIndivior0.00%+2.29%+1.72%+23.69%+181.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$218.06+1.1%$232.15$160.86▼$250.74$13.60B0.39546,697 shs405,008 shsBBIOBridgeBio Pharma$66.80-1.1%$70.22$38.57▼$84.94$13.08B0.972.71 million shs1.55 million shsGMABGenmab A/S$25.08-0.6%$26.76$20.23▼$35.43$15.64B0.851.86 million shs1.11 million shsINDVIndivior$38.48+0.9%$35.44$13.45▼$41.00$4.69B0.881.68 million shs627,489 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S0.00%+3.62%-11.17%-3.50%+26.99%BBIOBridgeBio Pharma0.00%-1.20%-4.11%-3.76%+71.06%GMABGenmab A/S0.00%-0.28%-6.77%-4.06%+10.83%INDVIndivior0.00%+2.29%+1.72%+23.69%+181.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$295.3935.46% UpsideBBIOBridgeBio Pharma 2.85Moderate Buy$89.5934.12% UpsideGMABGenmab A/S 2.75Moderate Buy$37.9351.23% UpsideINDVIndivior 3.00Buy$39.332.22% UpsideCurrent Analyst Ratings BreakdownLatest INDV, GMAB, BBIO, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026ASNDAscendis Pharma A/S OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/3/2026BBIOBridgeBio Pharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$104.005/28/2026BBIOBridgeBio Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$94.00 ➝ $98.005/28/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$110.005/27/2026GMABGenmab A/S Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.005/26/2026BBIOBridgeBio Pharma Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/19/2026BBIOBridgeBio Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$82.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$355.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/15/2026BBIOBridgeBio Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/15/2026ASNDAscendis Pharma A/S EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$329.00(Data available from 6/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$865.78M15.71N/AN/A($2.97) per share-73.42BBIOBridgeBio Pharma$579.96M22.56N/AN/A($10.77) per share-6.20GMABGenmab A/S$3.72B4.20$1.61 per share15.58$9.10 per share2.76INDVIndivior$1.24B3.79$2.72 per share14.15($0.78) per share-49.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6725.1520.30N/A57.87%N/A-8.37%8/6/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A290.43N/A-124.42%N/A-65.81%8/4/2026 (Estimated)GMABGenmab A/S$963M$1.3219.0014.931.4921.05%15.34%8.94%8/6/2026 (Estimated)INDVIndivior$210M$1.9519.739.01N/A19.44%-219.26%29.40%7/30/2026 (Estimated)Latest INDV, GMAB, BBIO, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million3/31/2026Q1 2026INDVIndiviorN/A$0.96N/A$3.45N/A$317.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72BBIOBridgeBio PharmaN/A1.521.48GMABGenmab A/S0.872.182.17INDVIndiviorN/A0.860.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%GMABGenmab A/S7.07%INDVIndivior60.33%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma14.23%GMABGenmab A/S1.54%INDVIndivior0.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableGMABGenmab A/S3,029623.53 million613.93 millionOptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableINDV, GMAB, BBIO, and ASND HeadlinesRecent News About These CompaniesIs Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now?June 13 at 6:12 PM | insidermonkey.comRecent price trend in Indivior Pharmaceuticals Inc. (INDV) is your friend, here's whyJune 12 at 3:00 PM | msn.comINDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026June 12 at 11:22 AM | zacks.comIs Indivior Stock a Buy After Higher 2026 Guidance?June 12 at 11:16 AM | zacks.comINDV Stock: What Sublocade Growth Signals for 2026June 12 at 11:16 AM | zacks.comIndivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of "Buy" from BrokeragesJune 12 at 5:05 AM | americanbankingnews.comRyan Preblick Sells 36,000 Shares of Indivior (NASDAQ:INDV) StockJune 12 at 4:29 AM | americanbankingnews.comIndivior (NASDAQ:INDV) CFO Sells $1,357,200.00 in StockJune 11 at 7:23 AM | insidertrades.comIndivior: A Stronger Business Than When I First Covered ItJune 9, 2026 | seekingalpha.com5 Top-Ranked Efficient Stocks Beating Industry Peers on Key MetricsJune 2, 2026 | zacks.comWhat to Know About This Fund's $74.8 Million Indivior SaleMay 30, 2026 | finance.yahoo.comWhy a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%May 30, 2026 | aol.comAIndivior Pharmaceuticals Inc.May 24, 2026 | money.usnews.comDoes Indivior Pharmaceuticals Inc. (INDV) have the potential to rally 32.48% as Wall Street analysts expect?May 21, 2026 | msn.comNew Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare UtilizationMay 20, 2026 | globenewswire.comThe Bull Case For Indivior Pharmaceuticals (INDV) Could Change Following Upgraded Outlook And $175M Buyback - Learn WhyMay 20, 2026 | finance.yahoo.comIndivior Pharmaceuticals Inc. (INDV) Is a Great Choice for 'Trend' Investors, Here's WhyMay 18, 2026 | zacks.comBears are Losing Control Over Indivior Pharmaceuticals Inc. (INDV), Here's Why It's a 'Buy' NowMay 14, 2026 | zacks.comIndivior to Participate in Upcoming Investor ConferencesMay 14, 2026 | globenewswire.comA Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Strong Recent Share Price RunMay 11, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINDV, GMAB, BBIO, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$218.06 +2.46 (+1.14%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$218.30 +0.24 (+0.11%) As of 06/12/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$66.80 -0.75 (-1.11%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$66.81 +0.01 (+0.01%) As of 06/12/2026 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Genmab A/S NASDAQ:GMAB$25.08 -0.16 (-0.63%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$25.08 +0.01 (+0.02%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Indivior NASDAQ:INDV$38.48 +0.35 (+0.92%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$39.00 +0.52 (+1.35%) As of 06/12/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
